

# CITATION REPORT

List of articles citing

Systematic overview of warfarin and its drug and food interactions

DOI: 10.1001/archinte.165.10.1095

Archives of Internal Medicine, 2005, 165, 1095-106.

**Source:** <https://exaly.com/paper-pdf/39001391/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
837	Evaluation of knowledge of Health care professionals on warfarin interactions with drug and herb medicinal in Central Saudi Arabia. <b>2016</b> , 32, 229-33		8
836	Surgical preparation: anesthesia & hemostasis. <b>2005</b> , 11, 32-55		9
835	Recent Publications on Medications and Pharmacy. <b>2005</b> , 40, 722-724		
834	Clarithromycin extended-release in community-acquired respiratory tract infections. <b>2005</b> , 6, 2867-76		8
833	Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. <b>2005</b> , 117, 55-9; discussion 65-7		14
832	Effects of dietary supplements on hemostasis. <b>2005</b> , 117, 45-7; discussion 65-7		5
831	The interference of botanicals and nutraceuticals with the effects of antithrombotic agents: how should the available evidence be weighed?. <b>2005</b> , 117, 19-24; discussion 39-42		1
830	Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: A case report. <b>2005</b> , 3, 266-269		7
829	Management of venous thromboembolism in the elderly. <b>2006</b> , 23, 651-71		25
828	Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management. <b>2006</b> , 23, 13-25		23
827	The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. <b>2006</b> , 24, 1021-33		112
826	Careful management can reduce the risk of bleeding in elderly patients receiving vitamin K antagonist (VKA) therapy. <b>2006</b> , 22, 23-26		
825	Antibiotic drug interactions. <b>2006</b> , 90, 1223-55		43
824	Management of venous thromboembolism in patients with primary and metastatic brain tumors. <b>2006</b> , 24, 1310-8		125
823	Systematic overview of drug interactions with antidepressant medications. <b>2006</b> , 51, 300-16		37
822	Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. <b>2006</b> , 58, 426-33; discussion 426-33		15
821	Leflunomide and warfarin interaction: case report and review of the literature. <b>2006</b> , 26, 868-71		12

820	Best practice in primary care pathology: review 8. <b>2007</b> , 60, 740-8	13
819	Warfarin and its interactions with foods, herbs and other dietary supplements. <b>2006</b> , 5, 433-51	104
818	Drug interactions with warfarin: what clinicians need to know. <b>2007</b> , 177, 369-71	58
817	Interaction potential between cranberry juice and warfarin. <b>2007</b> , 64, 490-4	42
816	Interaction between lopinavir/ritonavir and warfarin. <b>2007</b> , 177, 357-9	33
815	Vitamin K antagonist use in the elderly: special considerations. <b>2007</b> , 3, 321-30	3
814	Potential drug-drug interactions within Veterans Affairs medical centers. <b>2007</b> , 64, 1500-5	22
813	Examining differences in weekly warfarin dose in patients with and without cancer. <b>2007</b> , 29, 638-43	5
812	Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. <b>2007</b> , 47, 70-7	18
811	The effect of hospitalization on oral anticoagulation control: a population-based study. <b>2007</b> , 119, 705-14	34
810	A warfarin-induced subconjunctival hemorrhage. <b>2007</b> , 78, 113-8	20
809	Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. <b>2007</b> , 8, 713-9	18
808	Bleeding, Hemostasis, and Transfusion Medicine. <b>2007</b> , 437-460	2
807	Potentialisation de la fluindione et de la warfarine par la dexaméthasone dans le myélome multiple et l'amylose AL. <b>2007</b> , 74, 845-851	
806	Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions. <b>2007</b> , 16, 309-15	26
805	Evidence-based use of medications in patients with coronary artery disease in a rural Australian community. <b>2007</b> , 15, 241-6	1
804	Inappropriate prescribing in the elderly. <b>2007</b> , 32, 113-21	293
803	Clinical risk management of herb-drug interactions. <b>2007</b> , 63, 258-67	47

802	Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. <b>2007</b> , 5, 1237-42	41
801	Interaction between warfarin and nafcillin: case report and review of the literature. <b>2007</b> , 27, 1467-70	19
800	Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. <b>2007</b> , 27, 1237-47	77
799	Potential of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <b>2007</b> , 74, 446-52	16
798	Interacties van geneesmiddelen met voeding, met medicinale planten en met andere geneesmiddelen. <b>2007</b> , 23, 12-22	
797	Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. <b>2007</b> , 63, 335-43	19
796	Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. <b>2007</b> , 29, 671-5	15
795	Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. <b>2008</b> , 25, 72-7	33
794	Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. <b>2008</b> , 8, 13	37
793	Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. <b>2008</b> , 6, 15	22
792	Potentially inappropriate prescribing to hospitalised patients. <b>2008</b> , 17, 733-7	26
791	Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. <b>2008</b> , 69, 1534-47	40
790	Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. <b>2008</b> , 22, 127-40	48
789	Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. <b>2008</b> , 84, 581-8	79
788	Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <b>2008</b> , 66, 76-81	74
787	Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. <b>2008</b> , 83, 312-21	195
786	CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. <b>2008</b> , 83, 460-70	312
785	Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. <b>2008</b> , 6, 1500-6	186

784	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , <b>2008</b> , 263, 412-9	10.8	10
783	Evaluation of a potential tigecycline-warfarin drug interaction. <b>2008</b> , 28, 895-905		16
782	Possible antiretroviral therapy-warfarin drug interaction. <b>2008</b> , 28, 945-9		26
781	Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. <b>2008</b> , 28, 960-7		37
780	Adverse drug reactions in patients with cardiovascular disease. <b>2008</b> , 33, 703-68		24
779	Corrección de dosis en pacientes anticoagulados. <b>2008</b> , 15, 589-591		
778	[Oral anticoagulation excess: analysis from an emergency department]. <b>2008</b> , 208, 66-70		1
777	Current issues in thromboprophylaxis in the elderly. <b>2008</b> , 25, 1049-60		3
776	Pharmacogenomics of 4-hydroxycoumarin anticoagulants. <b>2008</b> , 40, 355-75		79
775	Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. <b>2008</b> , 78, 247-64		13
774	Interaction between statins and clopidogrel: is there anything clinically relevant?. <b>2008</b> , 101, 915-25		35
773	Drugs affecting blood coagulation, fibrinolysis, and hemostasis. <b>2008</b> , 399-422		1
772	Azathioprine-induced warfarin resistance. <b>2008</b> , 42, 1118-23		24
771	Primary prevention of venous thromboembolism in long-term care: identifying and managing the risk. <b>2008</b> , 14, 149-58		13
770	Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. <b>2008</b> , 324, 139-48		36
769	Interaction between warfarin and Panax ginseng in ischemic stroke patients. <b>2008</b> , 14, 715-21		67
768	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 160S-198S		1648
767	The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. <b>2008</b> , 30, 276-81		26

766	Reducing the risk of thromboembolic events. <b>2008</b> , 3, 248-263	1
765	Enhanced Interaction between Warfarin and High-Dose Ketoconazole: A Case Report. <b>2009</b> , 2009, 315687	1
764	How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?. <b>2009</b> , 50, 83-8	13
763	Atrial fibrillation: pathogenesis, medical-surgical management and dental implications. <b>2009</b> , 140, 167-77; quiz 248	9
762	Management of patients on warfarin by general dental practitioners in South West Wales: continuing the audit cycle. <b>2009</b> , 206, E8; discussion 214-5	10
761	Drug-induced hematologic syndromes. <b>2009</b> , 2009, 495863	61
760	Comment: fatal intracranial bleed potentially due to a warfarin and influenza vaccine interaction. <b>2009</b> , 43, 1913; author reply 1913-4	
759	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <b>2009</b> , 11, 860-85	84
758	The Norwegian General Practice (NORGE) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. <b>2009</b> , 27, 153-9	149
757	Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. <b>2009</b> , 29, 1344-56	4
756	Interaction between gemfibrozil and warfarin: case report and review of the literature. <b>2009</b> , 29, 744-8	8
755	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <b>2009</b> , 84, 579-83	12
754	Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?. <b>2009</b> , 27, 293-9	31
753	Predictors of unstable anticoagulation in African Americans. <b>2009</b> , 27, 430-7	20
752	A cross-sectional study of the Anticoagulation Clinic in RIPAS Hospital, Brunei. <b>2009</b> , 28, 140-5	
751	Synthesis and insecticidal activity of new 4-hydroxy-2H-1-benzopyran-2-one derivatives. <b>2009</b> , 159, 768-77	5
750	Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. <b>2009</b> , 35, 603-12	48
749	Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. <b>2009</b> , 86, 425-9	42

748	WARFARIN THERAPY, VITAMIN K AND OTHER DIETARY FACTORS. <b>2009</b> , 66, 123-128	1
747	How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. <b>2010</b> , 32, 427-42	17
746	Use of warfarin in people with low glomerular filtration rate or on dialysis. <b>2009</b> , 22, 503-11	16
745	Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. <b>2009</b> , 158, 1536-47	15
744	The use of selective serotonin reuptake inhibitors in elderly patients. <b>2009</b> , 17, 242-53	15
743	The discovery of antibacterial agents using diversity-oriented synthesis. <b>2009</b> , 2446-62	100
742	Raltitrexed: optimism and reality. <b>2009</b> , 5, 1447-54	13
741	Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. <b>2009</b> , 43, 875-81	21
740	Estimation of the warfarin dose with clinical and pharmacogenetic data. <b>2009</b> , 360, 753-64	1161
739	The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. <b>2009</b> , 49, 824-30	36
738	Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. <b>2009</b> , 43, 1765-73	47
737	What affects anticoagulation control in patients taking warfarin?. <b>2009</b> , 59, 590-4	2
736	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. <b>2009</b> , 30, 2969-77c	136
735	Warfarin initiation nomograms for venous thromboembolism. <b>2009</b> ,	1
734	Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. <b>2010</b> , 38, S126-35	33
733	Will there be a role for genotyping in warfarin therapy?. <b>2010</b> , 17, 439-43	6
732	Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. <b>2010</b> , 25, 312-20	25
731	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <b>2010</b> ,	0

730	Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction. <b>2010</b> , 103, 1063-5	4
729	Mechanisms and Consequences of Drug-Drug Interactions. <b>2010</b> , 1	
728	Anticoagulants. <b>2010</b> , 365-408	9
727	Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study. <b>2010</b> , 66, 97-103	26
726	Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke. <b>2010</b> , 66, 643-4	11
725	Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. <b>2010</b> , 27, 400-11	12
724	Reversal of vitamin K antagonists prior to urgent surgery. <b>2010</b> , 57, 458-67	15
723	Management of Pulmonary Embolism: 2010 State-of-the-Art Update. <b>2010</b> , 12, 168-84	
722	Warfarin: history, tautomerism and activity. <b>2010</b> , 24, 553-73	44
721	Current thoughts on treatment of patients receiving anticoagulation therapy. <b>2010</b> , 68, 2879-87	24
720	Inhibition of warfarin hydroxylation by major tanshinones of Danshen ( <i>Salvia miltiorrhiza</i> ) in the rat in vitro and in vivo. <b>2010</b> , 17, 219-26	46
719	Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. <b>2010</b> , 17, 203-11	41
718	An integrative method for scoring candidate genes from association studies: application to warfarin dosing. <b>2010</b> , 11 Suppl 9, S9	14
717	Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. <b>2010</b> , 32, 347-56	3
716	Loco-regional anaesthesia for ocular surgery: Anticoagulant and antiplatelet drugs. <b>2010</b> , 21, 158-163	6
715	Warfarin: an environment-dependent switchable molecular probe. <b>2010</b> , 23, 604-8	19
714	Iron-catalyzed Michael reactions revisited: a synthetically useful process for the preparation of tri-carbonyl compounds and chiral warfarin. <b>2010</b> , 51, 3836-3839	30
713	Pharmacological effects of <i>Salvia miltiorrhiza</i> (Danshen) on cerebral infarction. <b>2010</b> , 5, 22	51

712	Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. <b>2010</b> , 8, 2418-27	42
711	Warfarin therapy: how the less interesting half just got interesting. <b>2010</b> , 8, 2705-7	7
710	The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. <b>2010</b> , 58, 1475-80	16
709	Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. <b>2010</b> , 106, 263-8	24
708	Warfarin and vitamin K intake in the era of pharmacogenetics. <b>2010</b> , 70, 164-70	46
707	Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. <b>2010</b> , 70, 139-42	21
706	CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. <b>2010</b> , 70, 234-40	58
705	Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. <b>2010</b> , 149, 598-605	26
704	Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. <b>2010</b> , 87, 57-64	106
703	Integration of genetic, clinical, and INR data to refine warfarin dosing. <b>2010</b> , 87, 572-8	184
702	Pharmacologic Interactions in the CICU. <b>2010</b> , 516-531	1
701	Update on Rivaroxaban. <b>2010</b> , 3, CMBD.S5101	
700	Minimizing the risks of anticoagulants and platelet inhibitors. <b>2010</b> , 121, 1960-70	26
699	Probable interaction between warfarin and bee pollen. <b>2010</b> , 67, 2034-7	11
698	Preemptive dose reduction of warfarin in patients initiating metronidazole. <b>2010</b> , 25, 35-9	3
697	Predisposing preventable factors in patients with bleeding due to warfarin usage: Evaluation of 114 patients. <b>2010</b> , 16, 684-7	5
696	Adverse drug reactions in older people. <b>2010</b> , 20, 246-259	11
695	Rodenticides. <b>2010</b> , 2153-2217	3

694	Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy. <b>2010</b> , 31, 719-30	6
693	Optimizing use of current anticoagulants. <b>2010</b> , 24, 717-26, viii	9
692	Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. <b>2010</b> , 33, 667-75	56
691	An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone. <b>2010</b> , 50, 693-8	13
690	Hydroxywarfarin metabolites potentially inhibit CYP2C9 metabolism of S-warfarin. <b>2010</b> , 23, 939-45	28
689	Warfarin maintenance dose in older patients: higher average dose and wider dose frequency distribution in patients of African ancestry than those of European ancestry. <b>2010</b> , 45, 93-7	9
688	Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: Does medication use predict worse outcome?. <b>2010</b> , 112, 275-81	32
687	A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. <b>2010</b> , 125, e259-64	47
686	Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. <b>2010</b> , 126, e383-8	13
685	[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]. <b>2010</b> , 31, 361-8	3
684	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <b>2010</b> , 159, 331-9	345
683	Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. <b>2010</b> , 123, 151-7	60
682	Cranberry juice and warfarin: when bad publicity trumps science. <b>2010</b> , 123, 384-92	32
681	Outpatient management of patients following pulmonary embolism. <b>2010</b> , 123, 987-90	1
680	Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. <b>2010</b> , 27, 759-70	41
679	Patient factors that influence warfarin dose response. <b>2010</b> , 23, 194-204	28
678	Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. <b>2011</b> , 11, 265-75	11
677	Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. <b>2011</b> , 45, 701-12	20

676	Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. <b>2011</b> , 51, 1051-60	38
675	Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. <b>2011</b> , 51, 561-74	20
674	Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INR response after vitamin K administration. <b>2011</b> , 124, 527-33	11
673	Potentially harmful drug-drug interactions in the elderly: a review. <b>2011</b> , 9, 364-77	167
672	Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype. <b>2011</b> , 412, 2343-5	3
671	Raltitrexed in mesothelioma. <b>2011</b> , 11, 1481-90	15
670	"Zeus" a new oral anticoagulant therapy dosing algorithm: a cohort study. <b>2011</b> , 128, 325-30	11
669	Severe INR elevation related to duloxetine use: a case report. <b>2011</b> , 52, 583-5	3
668	Potentially serious drug-drug interactions among community-dwelling older adult dental patients. <b>2011</b> , 112, 153-60	3
667	Pharmacological adherence to oral anticoagulant and factors that influence the international normalized ratio stability. <b>2011</b> , 19, 18-25	13
666	Pharmacologic Adjuncts to Endovascular Procedures. <b>2011</b> , 807-813	1
665	Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates. <b>2011</b> , 106, 1062-8	12
664	Treatment for tobacco dependence: a potential application for stratified medicine?. <b>2011</b> , 8, 571-579	2
663	Complementary and Alternative Medicines Use in Patients on Warfarin and Matched Controls: A Retrospective Cohort Study. <b>2011</b> , 41, 265-270	1
662	Mtrorragies en dehors des pathologies de la grossesse. <b>2011</b> , 6, 1-12	
661	Antivitamines K: pharmacologie et pharmacoghtique. <b>2011</b> , 6, 1-9	
660	Toxicities by herbal medicines with emphasis to traditional Chinese medicine. <b>2011</b> , 12, 989-96	111
659	Oral anticoagulation: a review of the current and emerging therapies. <b>2011</b> , 24, 60-6	4

658	The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. <b>2011</b> , 224, 293-300	4
657	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. <b>2011</b> , 2, 1437-53	22
656	Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. <b>2011</b> , 36, 64-70	7
655	Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. <b>2011</b> , 71, 232-6	16
654	Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. <b>2011</b> , 71, 254-62	16
653	Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. <b>2011</b> , 9, 711-8	23
652	Multivitamin supplement interaction with warfarin therapy. <b>2011</b> , 30, 41-2	3
651	Bleeding risk with oral anticoagulation--new frontiers and new questions. <b>2011</b> , 65, 719-21	
650	The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. <b>2011</b> , 6, 228-40	38
649	The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. <b>2011</b> , 89, 408-15	94
648	The dental patient on oral anticoagulant medication: a literature review. <b>2011</b> , 38, 615-33	7
647	Contemporary management of transient ischemic attack: role of the pharmacist. <b>2011</b> , 31, 193-213	4
646	Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. <b>2011</b> , 33, 36-45	17
645	Multiple intracerebral hemorrhages in an elderly patient after adding quetiapine to a stable warfarin regimen. <b>2011</b> , 33, 302.e1-2	7
644	Analysis of the quality of prescriptions at a cardiovascular ward in Brazil: a pilot study. <b>2011</b> , 33, 260-3	
643	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <b>2011</b> , 31, 326-43	173
642	The effects of vitamin C on vitamin K-related clotting factors. <b>2011</b> , 20, 513-517	1
641	Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. <b>2011</b> , 67, 309-14	30

640	The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. <b>2011</b> , 67, 581-90	10
639	Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database. <b>2011</b> , 67, 941-51	25
638	Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic. <b>2011</b> , 67, 1169-74	18
637	Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. <b>2011</b> , 67, 1119-30	34
636	Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. <b>2011</b> , 410, 68-74	22
635	Gestion des accidents des anticoagulants chez le sujet âgé en médecine d'urgence. <b>2011</b> , 3, 83-89	
634	Personalized medicine: understanding probabilities and managing expectations. <b>2011</b> , 26, 204-6	15
633	Stroke prevention in atrial fibrillation: atrial appendage closure. <b>2011</b> , 13, 159-66	29
632	Using highly variable warfarin dosing to identify patients at risk for adverse events. <b>2011</b> , 9, 14	1
631	An automated database case definition for serious bleeding related to oral anticoagulant use. <b>2011</b> , 20, 560-6	230
630	Adverse effects of concentrated green tea extracts. <b>2011</b> , 55, 874-85	53
629	Emergency department management of patients on warfarin therapy. <b>2011</b> , 58, 192-9	4
628	Drug Interactions Involving Warfarin: Practice Tool and Practical Management Tips. <b>2011</b> , 144, 21-25.e9	21
627	Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. <b>2011</b> , 45, 881-7	15
626	Adverse Drug Reactions and Drug-drug Interactions. <b>2011</b> , 1569-1589	1
625	Measurement of warfarin in the oral fluid of patients undergoing anticoagulant oral therapy. <b>2011</b> , 6, e28182	33
624	Reliability and validity of 5 databases for the identification of warfarin-medication interactions. <b>2011</b> , 17, E95-7	2
623	Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. <b>2011</b> , 139, 1130-1139	36

622	Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. <b>2011</b> , 42, 3477-83	28
621	Cytochrome P450-mediated cardiovascular drug interactions. <b>2011</b> , 7, 1065-82	21
620	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. <b>2011</b> , 32, 1968-76, 1976a	42
619	HIV-Associated Venous Thromboembolism. <b>2011</b> , 3, e2011030	86
618	The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study. <b>2011</b> , 17 Suppl 1, S54-7	9
617	Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference. <b>2011</b> , 68, 941-6	18
616	The safety of cruciferous plants in humans: a systematic review. <b>2012</b> , 2012, 503241	10
615	Laparotomy for a patient with warfarin-induced large bowel obstruction. <b>2012</b> , 57, 247	0
614	Interventions to improve anticoagulation with warfarin. <b>2012</b> , 34, 209-16	5
613	A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. <b>2012</b> , 11, 55-61	3
612	Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. <b>2012</b> , 11, 45-54	1
611	Probable warfarin and dapson interaction. <b>2012</b> , 18, 107-9	5
610	Novel microtubule-targeted agent 6-chloro-4-(methoxyphenyl) coumarin induces G2-M arrest and apoptosis in HeLa cells. <b>2012</b> , 33, 407-17	24
609	Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. <b>2012</b> , 91, 777-86	6
608	Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. <b>2012</b> , 38, 893-904	39
607	Vitamin K-dependent carboxylation of osteocalcin: friend or foe?. <b>2012</b> , 3, 149-57	127
606	Evaluation of the B-SAFE campaign to reduce clinically significant warfarin-drug interactions among fee-for-service Medicare beneficiaries. <b>2012</b> , 27, 518-23	2
605	Novel anticoagulants in atrial fibrillation stroke prevention. <b>2012</b> , 3, 123-36	15

604	Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study. <b>2012</b> , 2,	21
603	Documentation of Warfarin Education provided to Hospital Patients: A Clinical Audit. <b>2012</b> , 42, 129-133	0
602	Vitamin K for improved anticoagulation control in patients receiving warfarin. <b>2012</b> ,	
601	A population-based assessment of the drug interaction between levothyroxine and warfarin. <b>2012</b> , 92, 766-70	17
600	Soft Drugs. <b>2012</b> , 77-258	
599	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. <b>2012</b> , 107, 1035-43	21
598	Vitamin K antagonists. Ready to be replaced?. <b>2012</b> , 32, 249-57	8
597	Metrorragie al di fuori delle patologie della gravidanza. <b>2012</b> , 16, 1-12	
596	Increased Warfarin Requirements during Concurrent Dicloxacillin Therapy. <b>2012</b> , 28, 197-200	1
595	Current anticoagulant safety. <b>2012</b> , 11, 401-13	4
594	Synthesis, growth and vibrational spectroscopic study of a novel coumarinoylthiazole. <b>2012</b> , 97, 1125-32	3
593	Total synthesis of infectopyrone, aplysiopsenes A&Ugrave;, ent-aplysiopsene D, phomapyrones A and D, 8,9-dehydroxylarone, and nectriapyrone. <b>2012</b> , 68, 7280-7287	23
592	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. <b>2012</b> , 129, 9-16	7
591	Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. <b>2012</b> , 125, 183-9	78
590	Warfarin use in nursing home residents: results from the 2004 national nursing home survey. <b>2012</b> , 10, 25-36.e2	18
589	Coleus forskohlii extract induces hepatic cytochrome P450 enzymes in mice. <b>2012</b> , 50, 750-5	21
588	Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. <b>2012</b> , 90, 1244-53	56
587	An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. <b>2012</b> , 108, 476-84	120

586	Hepatic cytochrome P450 mediates interaction between warfarin and <i>Coleus forskohlii</i> extract in vivo and in vitro. <b>2012</b> , 64, 1793-801	20
585	Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review. <b>2012</b> , 32, 131-7	7
584	Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic. <b>2012</b> , 10, 352-60	22
583	Screening for anemia in patients on warfarin facilitates diagnosis of gastrointestinal malignancies and pre-malignant lesions. <b>2012</b> , 130, e20-5	10
582	Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulants. <b>2012</b> , 130, 291-301	14
581	Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. <b>2012</b> , 136, 186-201	82
580	The need for translational research on drug-drug interactions. <b>2012</b> , 91, 771-3	18
579	Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. <b>2012</b> , 107, 253-9	126
578	Bleeding risks and response to therapy in patients with INR higher than 9. <b>2012</b> , 138, 546-50	2
577	The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy. <b>2012</b> , 29, 307-17	9
576	A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. <b>2012</b> , 107, 1083-91	39
575	. <b>2012</b> ,	15
574	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. <b>2012</b> , 7, 49-59	10
573	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e44S-e88S	1112
572	Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. <b>2012</b> , 88, 185-94	35
571	Dabigatran etexilate: what do hospitalists need to know?. <b>2012</b> , 7, 262-9	4
570	Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. <b>2012</b> , 32, 304-13	35
569	Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. <b>2012</b> , 22, 176-82	32

568	Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e152S-e184S	920
567	Establishing a flow process to coumarin-8-carbaldehydes as important synthetic scaffolds. <b>2012</b> , 18, 9901-10	33
566	Asymmetric and Diastereoselective Conjugate Addition Reactions: C=C Bond Formation at Large Scale. <b>2012</b> , 16, 1258-1272	92
565	Apixaban: an oral direct factor-xa inhibitor. <b>2012</b> , 29, 187-201	12
564	Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. <b>2012</b> , 68, 617-27	8
563	Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation. <b>2012</b> , 41, 146-56	6
562	Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. <b>2012</b> , 34, 1569-82	23
561	The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. <b>2012</b> , 34, 1592-600	11
560	High-risk antimicrobial prescriptions among ambulatory patients on warfarin. <b>2012</b> , 37, 157-60	12
559	Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. <b>2012</b> , 37, 505-9	10
558	Prothrombin time tests on a microfluidic disc analyzer. <b>2012</b> , 161, 1184-1190	13
557	Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes. <b>2012</b> , 19, 648-57	9
556	Oral anticoagulant-associated intracerebral hemorrhage. <b>2012</b> , 259, 212-24	76
555	Evaluation of food-drug interaction of guava leaf tea. <b>2013</b> , 27, 299-305	11
554	Synthesis, characterization, in vitro antimicrobial, and U2OS tumoricidal activities of different coumarin derivatives. <b>2013</b> , 7, 68	17
553	Peculiarities of determining the content of 3-substituted 4-hydroxycoumarins in disinfectants and drugs. <b>2013</b> , 47, 109-117	2
552	Participant perspectives from the Indian Health Service Anticoagulation Training Program. <b>2013</b> , 35, 1091-8	1
551	Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital. <b>2013</b> , 69, 617-27	10

550	Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. <b>2013</b> , 69, 641-6	11
549	A probable clinically significant interaction between warfarin and cloxacillin: three case reports. <b>2013</b> , 69, 721-4	10
548	Effect of flavonoids on circulating levels of TNF- $\alpha$ and IL-6 in humans: a systematic review and meta-analysis. <b>2013</b> , 57, 784-801	56
547	Disadvantages of VKA and requirements for novel anticoagulants. <b>2013</b> , 26, 103-14	31
546	Transcatheter left atrial appendage occlusion. <b>2013</b> , 31, 363-84	1
545	Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement. <b>2013</b> , 11, 555-72	1
544	Determination of total and unbound warfarin and warfarin alcohols in human plasma by high performance liquid chromatography with fluorescence detection. <b>2013</b> , 1314, 54-62	27
543	Integrating dietary supplements into cancer care. <b>2013</b> , 12, 369-84	39
542	Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. <b>2013</b> , 29, S34-44	31
541	Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. <b>2013</b> , 31, 971-80	32
540	Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review. <b>2013</b> , 69, 1985-96	44
539	Nuevos anticoagulantes frente a anticoagulantes clásicos: ventajas e inconvenientes. <b>2013</b> , 39, 10-16	3
538	Factors associated with statin selection among privately insured commercial and Medicare patients. <b>2013</b> , 29, 395-404	1
537	New avenues for anticoagulation in atrial fibrillation. <b>2013</b> , 93, 68-77	20
536	Anticoagulant Drugs: Current and Novel. <b>2013</b> , 113-141	1
535	Stroke prevention in atrial fibrillation in heart failure. <b>2013</b> , 9, 427-35, viii	2
534	Atrial fibrillation in heart failure in the older population. <b>2013</b> , 9, 451-9, viii-ix	3
533	[Bleedings during vitamin K antagonist therapy associated with ciclosporin and rifampicin]. <b>2013</b> , 42, 908-11	1

532	Managing bleeding in anticoagulated patients in the emergency care setting. <b>2013</b> , 45, 467-77	20
531	Fresh frozen plasma dosing for warfarin reversal: a practical formula. <b>2013</b> , 88, 244-50	7
530	Participation of iatrogenically coagulopathic patients in wilderness activities. <b>2013</b> , 24, 257-66	5
529	Sex differences in the effective warfarin dosage in Han and aboriginal Taiwanese patients with the VKORC1-1639AA genotype. <b>2013</b> , 25, 213-217	1
528	Rapid reversal of warfarin-associated hemorrhage in the emergency department by prothrombin complex concentrates. <b>2013</b> , 62, 616-626.e8	14
527	Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. <b>2013</b> , 35, 1201-10	31
526	Dose-adjusted warfarin: writing the prescription is only the beginning. <b>2013</b> , 46, 51-3	
525	[Improvements in oral anticoagulant therapy for atrial fibrillation]. <b>2013</b> , 141, 487-93	2
524	The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. <b>2013</b> , 75, 208-16	25
523	Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. <b>2013</b> , 61, 143-50	22
522	Managing anticoagulation for atrial fibrillation: current issues and future strategies. <i>Journal of Internal Medicine</i> , <b>2013</b> , 273, 31-41	10.8 7
521	Facile Synthesis of Furowarfarins via Hetero-Diels-Alder Cycloaddition Reaction. <b>2013</b> , 43, 775-783	2
520	Atrial fibrillation and stroke prevention: is warfarin still an option? Yes: Debate at the Controversies in Neurology Congress, Beijing, October 2011. <b>2013</b> , 120, 1447-51	5
519	Bleeding risks associated with vitamin K antagonists. <b>2013</b> , 27, 111-8	13
518	Decision support system for Warfarin therapy management using Bayesian networks. <b>2013</b> , 55, 488-498	40
517	[Anticoagulation of older patients: what is new?]. <b>2013</b> , 42, 187-96	3
516	Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. <b>2013</b> , 168, 2540-7	40
515	Practical advice for prescribing in old age. <b>2013</b> , 41, 9-12	3

514	Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <b>2013</b> , 128, 2622-703	183
513	The pharmacology and therapeutic use of dabigatran etexilate. <b>2013</b> , 53, 1-13	18
512	A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. <b>2013</b> , 41, 61-70	
511	Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. <b>2013</b> , 125, 146-57	
510	Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. <b>2013</b> , 14, 745-53	11
509	Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries. <b>2013</b> , 47, 1420-8	8
508	Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. <b>2013</b> , 28, 766-9	3
507	Clinical impact of temporary therapy interruptions on anticoagulation control in patients treated with warfarin. <b>2013</b> , 20, 267-74	
506	Pharmacogenetics. <b>2013</b> , 53-66	1
505	Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. <b>2013</b> , 70, 782-6	10
504	Completeness of prescription information in US commercial claims databases. <b>2013</b> , 22, 899-906	58
503	Novel Oral Anticoagulants and Atrial Fibrillation: Efficacy and Safety Considerations. <b>2013</b> , 74, 505-509	0
502	Warfarin initiation nomograms for venous thromboembolism. <b>2013</b> , CD007699	6
501	The need for multicentre cardiovascular clinical trials in Asia. <b>2013</b> , 10, 355-62	3
500	Outpatient Anticoagulant Therapy. <b>2013</b> , 698-716	
499	Usage of medications with high potential to interact with warfarin among atrial fibrillation residents in long-term care facilities. <b>2013</b> , 14, 165-73	2
498	The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. <b>2013</b> , 6, 677-95	30
497	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <b>2013</b> , CD008600	34

496	Eye, ear, nose, and throat emergencies in the elderly. 153-169	
495	Genitourinary and gynecologic emergencies in the elderly. 219-236	
494	Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. <b>2013</b> , 8, e63479	297
493	Current strategies to minimize the bleeding risk of warfarin. <b>2013</b> , 4, 89-99	24
492	Drug interactions between non-steroidal anti-inflammatory drugs and cardiovascular treatments (except anti-agregant therapy). <b>2013</b> , 12, 36-46	2
491	New oral anticoagulants. <b>2013</b> , 56, 57	1
490	Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. <b>2013</b> , 9, 81-8	5
489	A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. <b>2013</b> , 8, e64255	61
488	Structure-activity relationships of 3,3'-phenylmethylene-bis-4-hydroxycoumarins: selective and potent inhibitors of gram-positive bacteria. <b>2013</b> , 2013, 178649	7
487	New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. <b>2013</b> , 2013, 973710	12
486	Does warfarin help prevent ischemic stroke in patients presenting with post coronary bypass paroxysmal atrial fibrillation?. <b>2013</b> , 19, 207-11	10
485	Pharmacogenomics of Warfarin. <b>2014</b> , 497-507	
484	Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort. <b>2014</b> , 111, 912-22	12
483	Is point-of-care accurate for indicating thrombolysis in anticoagulated patients on oral anticoagulation treatments?. <b>2014</b> , 72, 487-9	5
482	Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. <b>2014</b> , 3, 695	14
481	Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. <b>2014</b> , 111, E1035-42	150
480	Hemostasis and Anticoagulants. <b>2014</b> , 479-496	2
479	Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update. <b>2014</b> , 13, 32-40	1

478	Implementation of pharmacist-managed anticoagulation clinic in a saudi arabian health center. <b>2014</b> , 49, 260-8	13
477	Updates on the clinical evidenced herb-warfarin interactions. <b>2014</b> , 2014, 957362	64
476	AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative. <b>2014</b> , 2014, 754147	2
475	Fungal Metabolites as Pharmaceuticals. <b>2014</b> , 67, 827	47
474	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. <b>2014</b> , 42, 153-62	1
473	Oral anticoagulants for Asian patients with atrial fibrillation. <b>2014</b> , 11, 290-303	27
472	Plant Poisons and Traditional Medicines. <b>2014</b> , 1128-1150.e6	3
471	Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. <b>2014</b> , 23, 974-83	17
470	Infrequent older adult-primary care provider discussion and documentation of dietary supplements. <b>2014</b> , 62, 1386-8	2
469	Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. <b>2014</b> , 348, 513-21	36
468	Which drug should we use for stroke prevention in atrial fibrillation?. <b>2014</b> , 29, 293-300	6
467	In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen. <b>2014</b> , 13, 226-39	8
466	Carbonyl reduction pathways in drug metabolism. <b>2014</b> , 46, 96-123	54
465	Induction of liver cytochrome P450s by Danshen-Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. <b>2014</b> , 154, 672-86	18
464	CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. <b>2014</b> , 66, 243-9	8
463	Comprehensive characterization of rodenticides in wastewater by liquid chromatography-tandem mass spectrometry. <b>2014</b> , 406, 345-58	17
462	Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. <b>2014</b> , 37, 542-8	1
461	L-Proline catalyzed multicomponent one-pot synthesis of gem-diheteroarylmethane derivatives using facile grinding operation under solvent-free conditions at room temperature. <b>2014</b> , 4, 7380	53

460	Synthesis of 4-hydroxy-3-[(E)-2-(6-substituted-9H-purin-9-yl)vinyl]coumarins as lipoxygenase inhibitors. <b>2014</b> , 55, 650-653	4
459	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. <b>2014</b> , 12, 5	26
458	Dosage individualization of warfarin using artificial neural networks. <b>2014</b> , 18, 371-9	14
457	Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. <b>2014</b> , 127, 657-663.e2	41
456	Percutaneous left atrial appendage closure: procedural techniques and outcomes. <b>2014</b> , 7, 1205-20	109
455	An organocatalyst from renewable materials for the synthesis of coumarins and chromenes: three-component reaction and multigram scale synthesis. <b>2014</b> , 4, 13708-13718	21
454	Haematology. <b>2014</b> , 212-275	3
453	Oral anticoagulants for stroke prevention in atrial fibrillation. <b>2014</b> , 39, 319-44	4
452	Treatments used in complementary and alternative medicine. <b>2014</b> , 889-898	2
451	Use of novel oral anticoagulants in patients with heart failure. <b>2014</b> , 16, 285	4
450	Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. <b>2014</b> , 31, 473-93	27
449	Effects of warfarin and L-carnitine on hemostatic function and oxidative stress in streptozotocin-induced diabetic rats. <b>2014</b> , 70, 535-46	12
448	Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. <b>2014</b> , 7 Suppl 1, S13	10
447	Impact de lâ€™antibioth�apie sur lâ€™anticoagulation par m�dicaments anti-vitamines K. <b>2014</b> , 49, 127-132	0
446	An analysis of the interactions between warfarin and Korean traditional herbal medicine in a Korean oriental hospital. <b>2014</b> , 6, 502-512	3
445	�Qu� aportan los nuevos anticoagulantes en la prevenci� del tromboembolismo venoso y arterial?. <b>2014</b> , 31, 102-109	
444	Anticoagulation in long-term care: how can we improve medication monitoring?. <b>2014</b> , 40, 10-5	1
443	Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. <b>2014</b> , 37, 1990-3	16

442	Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. <b>2014</b> , 23, 1160-7	11
441	Vitamin K for improved anticoagulation control in patients receiving warfarin. <b>2014</b> , CD009917	3
440	Is aspirin use associated with age-related macular degeneration? A meta-analysis. <b>2015</b> , 40, 144-54	15
439	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. <b>2015</b> , 148, 491-498	8
438	Total hip arthroplasty. 95-100	1
437	Regional versus general anesthesia and postoperative venous thromboembolism. 123-128	
436	Anticoagulants oraux directs chez la personne âgée, point de vue de l'anesthésiste-réanimateur. <b>2015</b> , 7, 107-112	
435	Antivitamins for Medicinal Applications. <b>2015</b> , 16, 1264-78	39
434	Synthesis of molecularly imprinted polypyrrole as an adsorbent for solid-phase extraction of warfarin from human plasma and urine. <b>2015</b> , 29, 1623-8	10
433	Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. <b>2015</b> , 26, 499-504	8
432	Delayed intracranial hemorrhage in the anticoagulated patient: A systematic review. <b>2015</b> , 79, 310-3	28
431	Percutaneous closure of the left atrial appendage for stroke prevention in atrial fibrillation: an alternative to lifelong anticoagulation?. <i>Critical Care Nursing Quarterly</i> , <b>2015</b> , 38, 371-84	2 1
430	Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor- $\alpha$ agonist, on the pharmacokinetics and pharmacodynamics of warfarin. <b>2015</b> , 9, 737-43	4
429	Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia. <b>2016</b> , 36, 91-100	1
428	DBU-promoted carboxylative cyclization of o-hydroxy- and o-acetamidoacetophenone. <b>2015</b> , 11, 906-12	20
427	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. <b>2015</b> , 10, 63-73	2
426	Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. <b>2015</b> , 10, e0144511	31
425	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <b>2015</b> , 351, h6223	18

424	Follow-up results of acute portal and splenic vein thrombosis with or without anticoagulation therapy after hepatobiliary and pancreatic surgery. <b>2015</b> , 88, 208-14		7
423	Rationale for Development of New Oral Anticoagulants. <b>2015</b> , 15, 89-91		
422	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <b>2015</b> , 75, 979-98		9
421	Aortic Atherosclerosis as an Embolic Source. <b>2015</b> , 1-64		
420	Anticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature. <b>2015</b> , 34, 269-77		
419	Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. <b>2015</b> , 5, e009518		6
418	Prothrombin Complex Concentrate (4PCC): A Review of its Use in Reversal of Vitamin K Antagonists. <b>2015</b> , 3, 50-54		
417	Reliability of thromboelastometry for detecting the safe coagulation threshold in patients taking acenocoumarol after elective heart valve replacement. <b>2015</b> , 136, 669-72		17
416	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. <i>Indian Heart Journal</i> , <b>2015</b> , 67 Suppl 2, S13-34	1.6	9
415	Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. <b>2015</b> , 38, 197-206		74
414	The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?. <b>2015</b> , 30, 315-9		18
413	[Drug-food interactions in internal medicine: What physicians should know?]. <b>2015</b> , 36, 530-9		11
412	Farmacología clínica comparada de los anticoagulantes orales: AVK y nuevos anticoagulantes. <b>2015</b> , 19, 1-5		
411	Tranexamic Acid Tamponade to Control Postoperative Surgical Hemorrhage. <b>2015</b> , 41, e82-9		4
410	Flavonoids at the pharma-nutrition interface: Is a therapeutic index in demand?. <b>2015</b> , 71, 102-7		27
409	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. <i>Journal of Internal Medicine</i> , <b>2015</b> , 278, 1-18	10.8	53
408	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. <b>2015</b> , 12, 2332-43		21
407	Effect of cocoa products and flavanols on platelet aggregation in humans: a systematic review. <b>2015</b> , 6, 2128-34		14

406	Left atrial appendage closure device in atrial fibrillation. <b>2015</b> , 7, 415-8	
405	Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. <b>2015</b> , 136, 250-60	41
404	Mobile compression devices and aspirin for VTE prophylaxis following simultaneous bilateral total knee arthroplasty. <b>2015</b> , 30, 447-50	11
403	Organobase catalyzed 1,4-conjugate addition of 4-hydroxycoumarin on chalcones: Synthesis, NMR and single-crystal X-ray diffraction studies of novel warfarin analogues. <b>2015</b> , 1094, 13-21	6
402	Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium. <b>2015</b> , 29, 181-94	5
401	Practical management of anticoagulation in patients with atrial fibrillation. <b>2015</b> , 65, 1340-1360	67
400	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. <b>2015</b> , 37, 2506-2514.e4	106
399	Thromboembolism Prophylaxis in Hip Arthroplasty: Routine and High Risk Patients. <b>2015</b> , 30, 2299-303	26
398	Review of cases of patient risk associated with ginseng abuse and misuse. <b>2015</b> , 39, 89-93	39
397	Checklists for the use of novel oral anticoagulants by the front-line clinician. <b>2015</b> , 148, 241-5	4
396	Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics. <b>2015</b> , 129, 954-62	20
395	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. <b>2015</b> , 108, 544-53	14
394	Dabigatran for the treatment of venous thromboembolism. <b>2015</b> , 8, 413-25	3
393	Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. <b>2015</b> , 65, 178-84	10
392	How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting. <b>2015</b> , 54, 517-25	4
391	Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. <b>2015</b> , 104, 244-56	13
390	A Comprehensive Review of Potential Warfarin-Fruit Interactions. <b>2015</b> , 28, 561-71	8
389	Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. <b>2015</b> , 30, 17-24	49

388	Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. <b>2016</b> , 29, 121-4		6
387	Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban. <b>2016</b> , 22, 499-502		24
386	Does hospital admission provide an opportunity for improving pharmacotherapy among elderly inpatients?. <b>2016</b> , 52, 391-401		2
385	New anticoagulants for the treatment of venous thromboembolism. <b>2016</b> , 42, 146-54		13
384	Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. <b>2016</b> , 57, 635-40		11
383	Use of novel oral anticoagulant agents in venous thromboembolism. <b>2016</b> , 6, 570-581		10
382	Design, Synthesis and Antifungal Activity of Coumarin Ring-Opening Derivatives. <i>Molecules</i> , <b>2016</b> , 21,	4.8	12
381	Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. <b>2016</b> , 11, e0157129		4
380	Combination Computing of Support Vector Machine, Support Vector Regression and Molecular Docking for Potential Cytochrome P450 1A2 Inhibitors. <b>2016</b> , 29, 629-634		1
379	Clinical Predictors Associated With Warfarin Sensitivity. <b>2016</b> , 23, e1690-e1694		7
378	Pharmacometabolomics in drug safety and drug-exposome interactions. <b>2016</b> , 12, 1		4
377	Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. <b>2016</b> , 67, 86-92		16
376	Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. <b>2016</b> , 27, 899-906		2
375	Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor. <b>2016</b> , 56, 1344-1354		7
374	CO as a C1 Source: B(CF)-Catalyzed Cyclization of o-Phenylene-diamines To Construct Benzimidazoles in the Presence of Hydrosilane. <b>2016</b> , 18, 6316-6319		52
373	Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan. <b>2016</b> , 55, 719-24		3
372	Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data. <b>2016</b> , 2, 17		1
371	Is the HAS-BLED score useful in predicting post-extraction bleeding in patients taking warfarin? A retrospective cohort study. <b>2016</b> , 6, e010471		12

- 370 Microwave-promoted Synthesis of Novel Fused Osthole Analogues. **2016**, 34, 1344-1352 1
- 369 Review of Top 10 Prescribed Drugs and Their Interaction with Dental Treatment. **2016**, 60, 421-34 8
- 368 Microwave-assisted synthesis and antifungal activity of novel coumarin derivatives: Pyrano[3,2-c]chromene-2,5-diones. **2016**, 116, 76-83 41
- 367 Omega-3 fatty acids as an adjunct for periodontal therapy-a review. **2016**, 20, 879-94 19
- 366 Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. **2016**, 109, 83-90 15
- 365 Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study. **2016**, 16, 267-274 2
- 364 The discovery of dabigatran etexilate for the treatment of venous thrombosis. **2016**, 11, 717-31 6
- 363 Farmacología clínica comparada de los anticoagulantes orales: antivitamina K y anticoagulantes orales directos. **2016**, 20, 1-5
- 362 Systemic Disease and Bleeding Disorders for the Oral and Maxillofacial Surgeon. **2016**, 28, 461-471 2
- 361 Warfarin and other vitamin K antagonists. **2016**, 521-530
- 360 Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis. **2016**, 30, 1007-18 4
- 359 Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism. **2016**, 12, 2265-2274 3
- 358 Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. **2016**, 11, 950-967 2
- 357 Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate. **2016**, 56, 39-46 7
- 356 A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. **2016**, 5, 171-186 15
- 355 Anticoagulation Therapy in Patients with Chronic Kidney Disease. **2017**, 906, 101-114 6
- 354 Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions. **2016**, 38, 1048-51 7
- 353 Nystatin and miconazole: pharmacological and clinical evidence regarding interactions with warfarin. **2016**, 22, 761-765 4

352	Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. <b>2016</b> , 41, 667-676		10
351	Coumarin anticoagulants. <b>2016</b> , 702-737		
350	Metabolism-Based Drug-Drug Interactions in Critically Ill Patients: Clinical Relevance and Predictability of In Vitro Systems. <b>2016</b> , 1-48		
349	Warfarin initiation nomograms for venous thromboembolism. <b>2016</b> , CD007699		7
348	Venous Thromboembolism in the Elderly. <b>2016</b> , 5, 132-139		2
347	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <b>2016</b> , 67, 2888-99		117
346	Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. <b>2016</b> , 42, 283-7		4
345	Anticoagulation-related nephropathy. <b>2016</b> , 14, 461-7		57
344	The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. <b>2016</b> , 31, 1299-1306		34
343	Bleeding associated with coadministration of rivaroxaban and clarithromycin. <b>2016</b> , 188, 669-672		19
342	Individualized approaches to thromboprophylaxis in atrial fibrillation. <b>2016</b> , 173, 143-58		9
341	Predictors of hospital mortality and serious complications in patients admitted with excessive warfarin anticoagulation. <b>2016</b> , 137, 79-84		4
340	Implication of coumarins towards central nervous system disorders. <b>2016</b> , 103, 188-203		74
339	Personalized Dose Finding Using Outcome Weighted Learning. <b>2016</b> , 111, 1509-1521		30
338	Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States. <b>2016</b> , 38, 545-56.e1-6		24
337	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2895	1.8	33
336	Microwave-assisted Synthesis and antifungal activity of coumarin[8,7-e][1,3]oxazine derivatives. <b>2016</b> , 20, 611-8		17
335	Reversal agents for NOACs: Connecting the dots. <i>Indian Heart Journal</i> , <b>2016</b> , 68, 559-63	1.6	6

334	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. <b>2016</b> , 16, 183-200	52
333	Anticoagulation in Older Adults with Multimorbidity. <b>2016</b> , 32, 331-46	10
332	Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. <b>2016</b> , 41, 187-205	70
331	The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. <b>2016</b> , 15, 131-9	11
330	PGWD: Integrating Personal Genome for Warfarin Dosing. <b>2016</b> , 8, 23-7	
329	Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. <b>2016</b> , 35, 1632-42	17
328	Coagulation assessment with the new generation of oral anticoagulants. <b>2016</b> , 33, 423-30	49
327	Comparison of the INR Values Measured by CoaguChek XS Coagulometer and Conventional Laboratory Methods in Patients on VKA Therapy. <b>2017</b> , 23, 187-194	15
326	Heart Failure and Mortality in Patients With Nonvalvular Atrial Fibrillation Started on Novel Oral Anticoagulant Therapy: A Single-Center Experience. <b>2017</b> , 23, 454-459	3
325	Edoxaban in patients with atrial fibrillation. <b>2017</b> , 11, 81-90	3
324	Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania. <b>2017</b> , 23, 438-444	4
323	Effect of gene polymorphisms on the warfarin treatment at initial stage. <b>2017</b> , 17, 47-52	12
322	Upper gastrointestinal bleeding in the setting of excessive warfarin anticoagulation: Risk factors, and clinical outcome. <b>2017</b> , 59, e128-e133	1
321	Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: Has Prescribing Improved?. <b>2017</b> , 23, 573-578	6
320	Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. <b>2017</b> , 32, 47-54	9
319	R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies. <b>2017</b> , 106, 1419-1425	10
318	Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. <b>2017</b> , 40, 1-7	4
317	Interaction of quercetin and its metabolites with warfarin: Displacement of warfarin from serum albumin and inhibition of CYP2C9 enzyme. <b>2017</b> , 88, 574-581	34

316	The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective. <b>2017</b> , 20, 599-605	3
315	Old and new oral anticoagulants: Food, herbal medicines and drug interactions. <b>2017</b> , 31, 193-203	129
314	Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS and CHADS-VASc score levels and warfarin prescription for adult patients with atrial fibrillation. <b>2017</b> , 17, 127	8
313	Unnecessary overuse. Study of "inadvisable practices" for patients with atrial fibrillation. <b>2017</b> , 217, 181-187	
312	Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. <b>2017</b> , 26, 1383-1390	10
311	Left Atrial Appendage Closure Device in Atrial Fibrillation. <b>2017</b> , 35, 297-300	2
310	Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. <b>2017</b> , 69, 2475-2484	158
309	Topical Antimycotics for Oral Candidiasis in Warfarin Users. <b>2017</b> , 120, 368-372	11
308	Venous thromboembolism in the elderly: A narrative review. <b>2017</b> , 155, 140-147	27
307	Anticoagulant Reversal and Anesthetic Considerations. <b>2017</b> , 35, 191-205	4
306	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <b>2017</b> , 4, CD008600	31
305	Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA. <b>2017</b> , 26, 767-778	4
304	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <b>2017</b> , 15, 454-464	2
303	Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. <b>2017</b> , 74, 1237-1244	48
302	A review of drug-drug interactions in older HIV-infected patients. <b>2017</b> , 10, 1329-1352	14
301	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <b>2017</b> , 33, 345-367	93
300	Combination of lenalidomide and low-dose dexamethasone therapy promotes the anticoagulant activity of warfarin in patients with immunoglobulin light-chain amyloidosis. <b>2017</b> , 14, 475-479	
299	Unnecessary overuse. Study of "inadvisable practices" for patients with atrial fibrillation. <b>2017</b> , 217, 181-187	0

298	Gingival bleeding, a possible "serious" adverse drug reaction: An observational study in the French Pharmacovigilance Database. <b>2017</b> , 44, 898-904	6
297	Mechanical mitral valve prosthesis: Should the INR be above 2 when aspirin is added to the oral anticoagulant?. <b>2017</b> , 25, 285-288	1
296	Assessment of Oral Anticoagulant Use in Residents of Long-Term Care Homes: Evidence for Contemporary Suboptimal Use. <b>2017</b> , 51, 1053-1062	3
295	Assessment of the Impact of L-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists. <b>2017</b> , 37, 929-936	
294	Anticoagulation-Related Nephropathy: Tip of the Iceberg. <b>2017</b> , 295-299	
293	Predicting drug interactions in addiction treatment. <b>2017</b> , 47, 872-878	1
292	Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. <b>2017</b> , 39, 1456-1478.e36	81
291	Monitoring and Reversal of Oral Anticoagulation in Hospitalized Patients. <b>2017</b> , 6, 330-347	
290	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. <b>2017</b> , 136, 215-221	3
289	The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective. <b>2017</b> , 20, 266-272	4
288	Randomized clinical study of the peri-implant healing to hydrophilic and hydrophobic implant surfaces in patients receiving anticoagulants. <b>2017</b> , 28, 1241-1247	8
287	Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. <b>2017</b> , 23, 301-318	32
286	Antiplatelet and Anticoagulant Therapies for Kawasaki Disease: Theory and Practice. <b>2017</b> , 355-372	1
285	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. <b>2017</b> , 83, 642-652	37
284	Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?. <b>2017</b> , 118, 82-92	70
283	Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants. <b>2017</b> , 10, 163-185	25
282	Synthesis and biological activity of the novel indanedione anticoagulant rodenticides containing fluorine. <b>2017</b> , 8, 92-98	2
281	Effects of Teicoplanin on the PT-INR Controlled by Warfarin in Infection Patients. <b>2017</b> , 137, 909-916	5

280	Big data system for information aggregation and model comparison for precision medicine. <b>2017</b> ,		0
279	Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. <b>2017</b> , 117, 2026-2033		9
278	Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches. <i>Molecules</i> , <b>2017</b> , 22,	4.8	9
277	Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study. <b>2017</b> , 12, e0175975		5
276	Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke. <b>2018</b> , 45, 529-535		10
275	International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by Quick and Owren reagents. <b>2018</b> , 56, 1698-1703		9
274	Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin. <b>2018</b> , 102, 912-921		22
273	Palladium-catalyzed site-selective arylation of aliphatic ketones enabled by a transient ligand. <b>2018</b> , 54, 2759-2762		28
272	Update of green tea interactions with cardiovascular drugs and putative mechanisms. <b>2018</b> , 26, S72-S77		23
271	The impact of aripiprazole on INR in a psychotic patient during warfarin therapy. <b>2018</b> , 28, 467-468		1
270	Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <b>2018</b> , 38, 588-596		23
269	The effect of lycopene on cytochrome P450 isoenzymes and P-glycoprotein by using human liver microsomes and Caco-2 cell monolayer model. <b>2018</b> , 69, 835-841		1
268	Early Response to Warfarin Initiation and the Risk of Venous Thromboembolism After Total Joint Arthroplasty. <b>2018</b> , 26, e90-e97		2
267	Effects of warfarin on biological processes other than haemostasis: A review. <b>2018</b> , 113, 19-32		10
266	Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants. <b>2018</b> , 24, 172-178		7
265	The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. <b>2018</b> , 21, 38-46		1
264	Selected Food/Herb-Drug Interactions: Mechanisms and Clinical Relevance. <b>2018</b> , 25, e423-e433		17
263	Cytostatic hydroxycoumarin OT52 induces ER/Golgi stress and STAT3 inhibition triggering non-canonical cell death and synergy with BH3 mimetics in lung cancer. <b>2018</b> , 416, 94-108		28

262	Effects of safflower injection on the pharmacodynamics and pharmacokinetics of warfarin in rats. <b>2018</b> , 48, 818-823	8
261	Expanding ambulatory care pharmacy services beyond anticoagulation. <b>2018</b> , 75, 1447-1448	
260	. <b>2018</b> ,	13
259	Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. <b>2018</b> , 13, e0208824	20
258	Catalytic Addition Reactions. <b>2018</b> , 147-173	
257	The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. <b>2018</b> , 7, 55-61	75
256	Current advances in the catalytic conversion of carbon dioxide by molecular catalysts: an update. <b>2018</b> , 47, 13281-13313	86
255	Real-World Safety of Anticoagulants. <b>2018</b> ,	
254	Palladium-Catalyzed $\alpha$ -Arylation of Ketones Using Amino Amide as a Transient Directing Group: Applications to Synthesis of Phenanthridinone Alkaloids. <b>2018</b> , 360, 3709-3715	24
253	Vitamin K antagonist use and renal function in pre-dialysis patients. <b>2018</b> , 10, 623-630	4
252	Flucloxacillin-warfarin interaction: an under-appreciated phenomenon. <b>2018</b> , 48, 860-863	3
251	Dicoumarol derivatives: Green synthesis and molecular modelling studies of their anti-LOX activity. <b>2018</b> , 80, 741-752	9
250	Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. <b>2018</b> , 74, 1061-1070	6
249	Seizure in cerebral venous and sinus thrombosis. <b>2018</b> , 3, 316-322	13
248	Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. <b>2018</b> , 18, 174	19
247	Review of Anticoagulants. <b>2018</b> , 99-108	
246	Drug-drug interactions involving antidepressants: focus on desvenlafaxine. <b>2018</b> , 14, 567-580	15
245	Common Medication Management Approaches for Older Adults in the Emergency Department. <b>2018</b> , 34, 415-433	4

244	Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases. <b>2018</b> , 27, 979-986		2
243	Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients. <b>2018</b> , 12, 207-216		12
242	Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. <b>2019</b> , 188, 101-108		15
241	A precision medicine approach to pharmacological adjuncts to extinction: a call to broaden research. <b>2019</b> , 236, 143-161		3
240	Successive waves of dipteran flies attracted to warfarin-intoxicated rabbit carcasses in Cairo, Egypt. <b>2019</b> , 80,		4
239	Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	2
238	Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. <b>2019</b> , 73, e13382		5
237	Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. <b>2019</b> , 13, 1363-1373		16
236	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. <b>2019</b> , 14, e0221500		9
235	Gut Microbiome and Response to Cardiovascular Drugs. <b>2019</b> , 12, 421-429		33
234	Umbelliferone derivatives exert neuroprotective effects by inhibiting monoamine oxidase A, self-amyloid aggregation, and lipid peroxidation. <b>2019</b> , 92, 103293		14
233	Manejo de la fibrilaci3n auricular no valvular desde la perspectiva del paciente en Espa1a. <b>2019</b> , 2, 37-46		1
232	Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. <b>2019</b> , 33, 551-561		2
231	Management of elderly ulcerative colitis in Japan. <b>2019</b> , 54, 571-586		12
230	Warfarin dose requirement in patients having severe thrombosis or thrombophilia. <b>2019</b> , 85, 1684-1691		3
229	Palladium-Catalyzed CâH Arylation of Aliphatic and Aromatic Ketones using Dipeptide Transient Directing Groups. <b>2019</b> , 8, 526-531		19
228	De Ritis ratio as a significant prognostic factor of international normalized ratio 14 in the initial 10 days of warfarin therapy. <b>2019</b> , 13, 1599-1607		0
227	Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. <b>2019</b> , 11, 2595-2620		10

226	Inhibitory Effects of Osthole on Human Breast Cancer Cell Progression via Induction of Cell Cycle Arrest, Mitochondrial Dysfunction, and ER Stress. <b>2019</b> , 11,	18
225	Base-Mediated One-pot Synthesis of Oxygen-Based Heterocycles from 2-Hydroxyphenyl-Substituted -Quinone Methides. <b>2019</b> , 84, 15978-15989	17
224	The research of synthesis and bioactivity of the novel indanedione anticoagulant rodenticides. <b>2019</b> , 26, 13833-13838	1
223	Pharmacologic Interactions. <b>2019</b> , 432-445.e7	
222	Adverse Drug Events, Medication Errors, and Drug Interactions. <b>2019</b> , 227-245	
221	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. <b>2019</b> , 59, 27-33	18
220	The New Anticoagulation Clinic. <b>2019</b> , 79-90	
219	A Framework Model for a Contextualized and Integrated Warfarin Therapy Case in a Master of Pharmacy Program. <b>2019</b> , 83, 6688	0
218	Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and CYP2C9 activity. <b>2019</b> , 25, 1599-1607	6
217	Outpatient Oral Anticoagulant Therapy. <b>2019</b> , 747-777	1
216	Acid Suppressive Therapy. <b>2020</b> , 18-31	
215	A study to evaluate herb-drug interaction underlying mechanisms: An investigation of ginsenosides attenuating the effect of warfarin on cardiovascular diseases. <b>2020</b> , 142, 105100	2
214	Role of direct oral anticoagulants in patients with kidney disease. <b>2020</b> , 97, 664-675	14
213	Acute Perioperative Pulmonary Embolism-Management Strategies and Outcomes. <b>2020</b> , 34, 1972-1984	4
212	Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. <b>2020</b> , 194, 240-245	14
211	Piperine Alters the Pharmacokinetics and Anticoagulation of Warfarin in Rats. <b>2020</b> , 12, 169-179	6
210	A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes. <b>2020</b> , 13, 718-726	0
209	Subtherapeutic INR due to warfarin interaction with smokeless tobacco. <b>2020</b> , 18, 2954-2957	0

208	Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation. <b>2020</b> , 8, 1008	0
207	Anticoagulation and antiplatelet therapy in patients with prosthetic heart valves. <b>2020</b> , 35, 3521-3529	2
206	Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. <b>2020</b> , 18, 347	1
205	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <b>2020</b> , 6, 52	3
204	Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. <b>2020</b> , 68, 1278-1284	6
203	Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant. <b>2020</b> , 11, 133-140	1
202	Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. <b>2020</b> , 10,	30
201	Rethinking potentially inappropriate medication use in nursing homes within the Chinese population. <b>2020</b> , 41, 724-729	
200	Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users. <b>2020</b> ,	
199	Chiral voltammetric sensor for warfarin enantiomers based on carbon black paste electrode modified by 3,4,9,10-perylenetetracarboxylic acid. <b>2020</b> , 861, 113986	11
198	Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD. <b>2020</b> , 70, 343-357	2
197	Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya. <b>2020</b> , 18, 165-173	1
196	Matrix Gla protein regulates adipogenesis and is serum marker of visceral adiposity. <b>2020</b> , 9, 68-76	9
195	CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. <b>2020</b> , 20, 687-694	5
194	Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. <b>2020</b> , 76, 867-876	11
193	Current formulation approaches in design and development of solid oral dosage forms through three-dimensional printing. <b>2020</b> , 5, 111-123	5
192	Doubly Robust Estimation of Optimal Dosing Strategies. <b>2021</b> , 116, 256-268	6
191	Toxicological effects of marine seaweeds: a cautious insight for human consumption. <b>2021</b> , 61, 500-521	9

190	Warfarin and food, herbal or dietary supplement interactions: A systematic review. <b>2021</b> , 87, 352-374	14
189	Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. <b>2021</b> , 51, 388-396	22
188	Drug-drug interaction between warfarin and statins: A Danish cohort study. <b>2021</b> , 87, 694-699	8
187	Drug Interactions. <b>2021</b> , 725-742.e3	1
186	Association Between the Prothrombin Time-International Normalized Ratio and Concomitant Use of Antibiotics in Warfarin Users: Focus on Type of Antibiotic and Susceptibility of to Antibiotics. <b>2021</b> , 55, 157-164	4
185	The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition?. <b>2021</b> , 45, E123-E129	0
184	Pickles and warfarin interaction: a case-based review. <b>2021</b> , 40, 1621-1624	3
183	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <b>2021</b> , 17, 19-38	6
182	Severe undernutrition increases bleeding risk on vitamin-K antagonists. <b>2021</b> , 40, 2237-2243	0
181	Association between Patients' Knowledge and Adherence to Anticoagulants, and Its Effect on Coagulation Control. <b>2021</b> , 106, 265-274	0
180	Antimycotic Treatment of Oral Candidiasis in Warfarin Users. <b>2021</b> , 134, e308-e312	2
179	Comparison of cardiovascular response between patients on warfarin and hypertensive patients not on warfarin during dental extraction. <b>2021</b> , 25, 2141-2150	0
178	Towards The Automated, Empirical Filtering of Drug-Drug Interaction Alerts in Clinical Decision Support Systems: Historical Cohort Study of Vitamin K Antagonists. <b>2021</b> , 9, e20862	0
177	Risk of over-anticoagulation during acute kidney injury in patients treated with vitamin K antagonists. <b>2021</b> ,	0
176	Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation. <b>2021</b> , 8, 20543581211046079	
175	Using machine learning to predict anticoagulation control in atrial fibrillation: A UK Clinical Practice Research Datalink study. <b>2021</b> , 25, 100688	0
174	Food-Drug Interaction in Older Adults. <b>2021</b> , 249-259	
173	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. <b>2021</b> , 35, 273-281	5

172	Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia. <b>2021</b> , 12, 189-195	1
171	Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism - A Retrospective Observational Study. <b>2021</b> ,	1
170	Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report. <b>2021</b> , 8971900211008623	2
169	Safety and Efficacy of Vitamin K Antagonists vs. Novel Oral Anticoagulants in Patients With Left Ventricular Thrombus: A Meta-Analysis. <b>2021</b> , 8, 636491	0
168	The Use of Active Comparators in Self-Controlled Designs. <b>2021</b> , 190, 2181-2187	2
167	Stability of Warfarin in Spiked-Saliva Using the Fluorometric HPLC Method. 1162, 180-190	1
166	Drug-drug interactions between vitamin K antagonists and statins: a systematic review. <b>2021</b> , 77, 1435-1441	2
165	Drug-drug interactions with warfarin: A systematic review and meta-analysis. <b>2021</b> , 87, 4051-4100	10
164	An efficient approach for the synthesis and antimicrobial evaluation of some new benzocoumarins and related compounds. <b>2021</b> , 51, 2175-2186	
163	Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation and Concomitant Liver Cirrhosis: A Systematic Review and Meta-Analysis. <b>2021</b> , 1	3
162	Unexpected acute pulmonary embolism in an old COVID-19 patient with warfarin overdose: a case report. <b>2021</b> , 5, ytab206	1
161	Palladium-Catalyzed $\alpha$ -(sp)-H Arylation of Aliphatic Ketones Enabled by a Transient Directing Group. <b>2021</b> , 86, 7296-7303	2
160	Evaluation of Time in Therapeutic Range in Patients with Cerebrovascular Disease Receiving Treatment with Warfarin.	
159	Design, multistep synthesis and in-vitro antimicrobial and antioxidant screening of coumarin clubbed chalcone hybrids through molecular hybridization approach. <b>2021</b> , 14, 103154	6
158	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. <b>2021</b> , 203, 121-130	2
157	Mechanistic study of bergamottin-induced inactivation of CYP2C9. <b>2021</b> , 153, 112278	2
156	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. <b>2021</b> , 174, 910-919	8
155	Patient-related factors associated with oral anticoagulation control: a population-based cohort study. <b>2021</b> , 29, 443-450	

154	Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. <b>2021</b> , 14, 1069-1080		
153	Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
152	Seasonal diet-based resistance to anticoagulant rodenticides in the fossorial water vole ( <i>Arvicola amphibius</i> ). <b>2021</b> , 200, 111422		1
151	Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). <b>2021</b> , 16, e0251665		0
150	Perioperative Antiplatelet and Anticoagulant Management with Endodontic Microsurgical Techniques. <b>2021</b> , 47, 1557-1565		0
149	Drug Usage in Surgical Patients: Preventing Medication-Related Problems. <b>2011</b> , 343-358		2
148	Vitamin K Antagonists and Their Limitations. <b>2013</b> , 33-40		1
147	ANTICOAGULANTS, THROMBOLYTIC AGENTS, AND ANTI-PLATELET DRUGS. <b>2009</b> , 449-556		1
146	Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin. <i>Medicine (United States)</i> , <b>2020</b> , 99, e22987	1.8	3
145	Crystal structure of 4-(4b,8a-di-hydro-9-pyrido[3,4-]indol-1-yl)-7-methyl-2-chromen-2-one. <b>2017</b> , 73, 56-58		1
144	Optimizing quality care for the oral vitamin K antagonists (VKAs). <b>2018</b> , 2018, 332-338		7
143	Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration. <b>2014</b> , 15, 45-8		7
142	Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. <b>2015</b> , 10, e0119043		20
141	Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. <b>2016</b> , 11, e0160713		3
140	Matrix Gla-protein and its role in vascular wall calcification. <b>2011</b> , 57, 96-112		2
139	Interaction between Traditional Chinese Medicine and Anticoagulant/Antiplatelet Drugs. <b>2019</b> , 20, 701-713		5
138	Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement. <b>2015</b> , 9, 129-38		1
137	Measuring prevalence, reliability and variation in high-risk prescribing in general practice using multilevel modelling of observational data in a population database. <b>2015</b> , 3, 1-140		7

136	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1	7
135	Strengths and limitations of standards of care to guide the orthopedic surgeon in VTE prevention. <b>2011</b> , 34, 121-8		1
134	General principles of warfarin interactions in orthopedic patients. <b>2008</b> , 31,		0
133	Selecting antithrombotic therapy for patients with atrial fibrillation. <b>2015</b> , 82, 49-63		3
132	Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. <b>2014</b> , 4, 314-23		9
131	Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism. <b>2015</b> , 128, 2147-53		14
130	Quality of anticoagulation therapy in neurological patients in a tertiary care hospital in north India. <b>2016</b> , 143, 428-33		5
129	Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole. <b>2016</b> , 20, 127-8		2
128	Influence of Flavonoids from Galium verum L. on the activities of cytochrome P450 isozymes and pharmacokinetic and pharmacodynamic of warfarin in rats. <b>2019</b> , 15, 645		1
127	Anticoagulants for cancer-associated ischemic stroke. <b>2019</b> , 31, 144-148		1
126	Protocol for the management of oral surgery patients on warfarin utilizing a Point-of-Care In-Office international normalized ratio monitoring device. <b>2013</b> , 03, 255-267		2
125	Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions. <b>2016</b> , 33, 299-303		7
124	Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. <b>2012</b> , 10, 9-16		5
123	Perioperative management of chronic anticoagulation in orthopaedic surgery. <b>2010</b> , 18, 729-38		19
122	Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area. <b>2013</b> , 24, 19-23		7
121	Lack of Association of Clinical Factors (SAmE-TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality. <b>2015</b> , 17, 192-8		10
120	Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos. <b>2010</b> , 30, 410		5
119	Pharmacotherapy in Spinal Cord Injuries. <b>2021</b> , 77-118		

- 118 Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?. **2021**, 66, 897-916 ○
- 117 Effect of NPC1L1 polymorphism on warfarin stable dose in Chinese patients under heart valve replacement surgery. **2021**,
- 116 Antithrombotic Agents. **2007**, 447-460
- 115 Pharmacological Interventions. **2007**, 81-107
- 114 Conventional Treatment of Deep Venous Thrombosis. **2007**, 381-394
- 113 Outpatient Anticoagulant Therapy. **2007**, 661-671
- 112 DEEP VEIN THROMBOSIS AND PREVENTION OF POST-THROMBOTIC SYNDROME. **2007**, 113-131
- 111 Relevant CYP450-mediated Drug Interactions in the ICU. **2009**, 870-877 3
- 110 Herbal Medicines – Introduction and General Information. **2009**, 1-30
- 109 Influence of Cardiovascular Medication on Nutritional Status. **2009**, 447-482
- 108 Case 44. Anticoagulation. **2009**,
- 107 Relevant CYP450-mediated Drug Interactions in the ICU. **2009**, 870-877
- 106 Public Health Concerns Related to Vitamin K Status. **2009**, 161-193
- 105 Duration of Anticoagulant Therapy After Venous Thromboembolism. **2010**, 363-385
- 104 Change in Prothrombin Time International Normalized Ratio due to Drug Interaction between Docetaxel and Warfarin. **2010**, 36, 802-806
- 103 Oral Anticoagulation. **2010**, 244-250
- 102 The vitamin K antagonists and their limitations. **2010**, 27-33
- 101 [Interactions between warfarin and natural products]. **2010**, 130, 1252-4 ○

100 A Case Analysis of Drug Interactions of Warfarin for Anticoagulant Service(ACS) Patients. **2010**, 27, 56-63

99 Medication Usage in Older Cardiothoracic Surgical Patients. **2011**, 241-257

98 Encyclopedia of Clinical Neuropsychology. **2011**, 2670-2671

97 DrugâNutrientâHerb interactions for commonly prescribed medications. **2011**, 901-922

96 Pulmonary Embolism. **2011**, 418-427

95 Postoperative Pain Management in Patients Receiving Antithrombotic Therapy Based on  
âContext-Sensitive AnalgesiaâUpper Abdominal Surgery-. **2011**, 31, 827-834

94 WarfarinâNutrition Interactions in the Hospice and Palliative Care Setting. **2011**, 427-434

93 METHOD OPTIMIZATION FOR ACETYLCHOLINESTERASE MODULATORS-ALBUMIN INTERACTIONS.  
**2011**, 80, 58-64

92 Pharmacology of Vitamin K Antagonists. 25-46

91 Retrospective Quality Assessment of Warfarin Therapy in Neurology Outpatients. **2011**, 28, 345-355

90 Genetics and Coronary Heart Disease. **2012**, 199-217

89 Proposal for Warfarin Dosage Guideline during Warfarin-Propafenone Combination Therapy. **2013**,  
30, 52-63

88 Ambulatory Warfarin Management. **2015**, 27-51

87 Oral surgery in patients under antithrombotic therapy. Narrative review.. **2015**, 4, 58-64

86 Role of anticoagulation in neurological practice. **2016**, 143, 392-4

85 Essential Pharmacogenomic Biomarkers in Clinical Practice. **2016**, 51-74

84 Concepts in Pharmacogenomics and Personalized Medicine. **2016**, 1-32

83 Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation. **2016**, 17-36

- 82 Introduction. **2016**, 1-6
- 81 Crystal structures of 4-methyl-2-oxo-2H-chromene-7,8-diyl di-acetate and 4-methyl-2-oxo-2H-chromene-7,8-diyl bis-(pent-4-ynoate). **2016**, 72, 704-8 ○
- 80 Review of Warfarin; A Cytochrome P450 Metabolizing Drug, in Clinical Practice. **2016**, 7, ○
- 79 Evidencia de sobreanticoagulación por warfarina en un hospital de segundo nivel de complejidad de Itagüe Antioquia. **2016**, 104-111
- 78 6-tert-Butyl-4-[(4-hydroxymethyl-2H-1,2,3-triazol-2-yl)methyl]-2H-chromen-2-one. **2016**, 1, ○
- 77 Prevalence of HIV in Hospitalized Patients with Venous Thrombosis of the Lower Limbs to the Abidjan Cardiological Institute. **2017**, 07, 435-441
- 76 Delayed Intracranial Hemorrhage in Patients Taking Warfarin with Head Trauma. **2017**, 1, 5127
- 75 De novo Design and in-silico Studies of Coumarin Derivatives as Inhibitors of Cyclin Dependent Kinase-2. **2017**, 4, 46-56
- 74 Management of Bleedings and Recurrent Venous Thromboembolism in Patients Receiving Vitamin K Antagonists. **2018**, 12, 50 1
- 73 Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus. **2019**, 56, 273-276 1
- 72 Encyclopedia of Clinical Neuropsychology. **2018**, 1-1
- 71 Encyclopedia of Clinical Neuropsychology. **2018**, 3677-3677
- 70 Medication-Related Problems in Surgical Patients. **2018**, 1-29
- 69 Anticoagulants and Treatment of Venous Thromboembolism. **2019**, 163-193
- 68 Medication Errors in Aging Adults: A Case-Based Approach to Medication Management. **2019**, 113-137
- 67 Medication-Related Problems in Surgical Patients. **2020**, 159-187
- 66 Direct oral anticoagulants: A new chapter in anticoagulation therapy. **2020**, 70, 249-268
- 65 Towards The Automated, Empirical Filtering of Drug-Drug Interaction Alerts in Clinical Decision Support Systems: Historical Cohort Study of Vitamin K Antagonists (Preprint).

64	Coffee, tea, and tobacco, interactions and other risks in patients at a neurological outpatient department. <b>2020</b> , 21, 130-134	
63	Development of Warfarin Talk: A Messenger Chatbot for Patients Taking Warfarin. <b>2020</b> , 30, 243-249	
62	. <b>2020</b> , 37-72	
61	Malignancy and Thrombosis. <b>2008</b> , 536-550	
60	Anticoagulation Therapy in Patients with Chronic Kidney Disease. <b>2015</b> ,	
59	Voriconazole-warfarin interaction necessitating warfarin dose management in an invasive aspergillosis patient: A case report. <b>2020</b> , 6, 12-15	
58	Progress toward genetic tailoring of heart failure therapy. <b>2010</b> , 12, 294-304	3
57	Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G. <b>2013</b> , 137, 203-9	7
56	Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. <b>2013</b> , 5, 40-54	22
55	Effect of galantamine on platelet functions in healthy elderly people. <b>2013</b> , 137, 977-80	
54	Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country. <b>2013</b> , 12, 175-82	12
53	Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. <b>2014</b> , 7, 376-84	25
52	Be careful before prescribing warfarin and octreotide together: a new drug-drug interaction report. <b>2014</b> , 18, 377	1
51	A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma. <b>2014</b> , 1,	
50	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents. <b>2013</b> , 6, 825	
49	Differences between warfarin and new oral anticoagulants in dental clinical practice. <b>2016</b> , 9, 151-156	6
48	Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study. <b>2019</b> , 18, 1010-1019	2
47	Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?. <b>2021</b> , 20, 339	1

46	Prevention of the post thrombotic syndrome with anticoagulation: a narrative review. <b>2021,</b>		2
45	The Random Effects Warfarin Days' Supply (REWarDS) model: Development and validation of a novel method to estimate exposure to warfarin using administrative data.. <b>2022,</b>		
44	Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study.. <b>2022,</b> 1		0
43	The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance. <b>2022,</b> 13-13		
42	Topical Miconazole Cream and Warfarin Interaction: A Case Report.. <b>2022,</b> 38, 127-129		1
41	Clinical Characteristics of HIV-Infected Patients with Venous Thromboembolism and Different CD4 T Lymphocyte Levels.. <b>2022,</b> 15, 613-620		
40	Micro-mechanical blood clot testing using smartphones.. <b>2022,</b> 13, 831		0
39	Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy.. <b>2022,</b>		0
38	Role of the Transplant Pharmacist.		
37	"In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.. <i>Journal of Clinical Medicine,</i> <b>2022,</b> 11,	5.1	1
36	Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: a cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting.. <i>Indian Heart Journal,</i> <b>2022,</b>	1.6	1
35	Recommendations from the ICM-VTE: General.. <i>Journal of Bone and Joint Surgery - Series A,</i> <b>2022,</b> 104, 4-162	5.6	0
34	Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions.. <i>Journal of Analytical Methods in Chemistry,</i> <b>2022,</b> 2022, 1900037	2	
33	Anticoagulation Monitoring in the Intensive Care Unit.. <i>Critical Care Nursing Quarterly,</i> <b>2022,</b> 45, 108-118 <sub>2</sub>		0
32	Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.. <i>Blood Advances,</i> <b>2022,</b>	7.8	
31	Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.. <i>Journal of Internal Medicine,</i> <b>2022,</b>	10.8	0
30	Drug interactions. <b>2013,</b> 730-746.e2		
29	Pharmacokinetics and Pharmacotherapeutics in Spinal Cord Injuries. <b>2022,</b> 169-216		

28	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> ,	6.4	3
27	Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1141 <sup>6.4</sup>		
26	Coumarin Derivatives Inhibit ADP-Induced Platelet Activation and Aggregation. <i>Molecules</i> , <b>2022</b> , 27, 4054.8		
25	Nutrients/Nutrition and Drug Interaction. <b>2022</b> , 285-307		
24	Atrial Fibrillation and Stroke.		
23	Spontaneous bilateral subdural hematoma in a patient with a prosthetic valve and association with plasmodium vivax malaria: A rare case report. <i>Annals of Medicine and Surgery</i> , <b>2022</b> , 80, 104191	2	○
22	Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement. <i>Medicine (United States)</i> , <b>2022</b> , 101, e29626	1.8	○
21	Time in therapeutic range with vitamin K antagonists in congenital heart disease: a multicenter study. <b>2022</b> ,		○
20	Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis.		○
19	Opposite Response to Vitamin K Antagonists: A Report of Two Cases and Systematic Review of Literature. <b>2022</b> , 12, 1578		1
18	Determination of Factors Affecting Time in Therapeutic Range in Patients on Warfarin Therapy. 109980042211279		
17	Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis. <b>2022</b> , 32, 238-250		○
16	Shared Decision-Making for Drug-Drug Interactions: Formative Evaluation of an Anticoagulant Drug Interaction. <b>2022</b> , 6, e40018		○
15	Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. <b>2022</b> ,		○
14	Fused-ring Pyrones from intramolecular C <sup>α</sup> H activation and their lipids-lowering activity associated with LXR-IDOL-LDLR axis regulation. <b>2022</b> , 114866		○
13	Warfarin (Coumadin). <b>2022</b> , 305-311		○
12	Pharmacokinetic and Pharmacologic Characterization of the Dihydratotetabenazine Isomers of Deutetabenazine and Valbenazine.		○
11	Antithrombotic Management in Spine Surgery in the Elderly. <b>2023</b> , 19-49		○

- 10 Coumarins as a base for the drug development: yes or no?. **2022**, 22, 27-36
- 9 A case of pulmonary embolism with bad warfarin anticoagulant effects caused by E. coli infection. **2023**, 18,
- 8 Nutritional Assessment of the Symptomatic Patient on a Plant-Based Diet: Seven Key Questions. **2023**, 15, 1387
- 7 Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.
- 6 The Implication of the Gut Microbiome in Heart Failure. **2023**, 12, 1158
- 5 Development and Validation of an Explainable Machine Learning-Based Prediction Model for Drug-Food Interactions from Chemical Structures. **2023**, 23, 3962
- 4 Relationship between elevated bilirubin levels and enhanced warfarin effects during biliary obstruction.
- 3 Summary of the clinical practice manual for late-onset hypogonadism.
- 2 Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study. Publish Ahead of Print,
- 1 Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population. **2023**,